NCT03357939View on ClinicalTrials.gov

Phase I Study of HLX3 vs Adalimumab in Chinese Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

January 12, 2017

Primary Completion Date

September 15, 2018

Study Completion Date

September 15, 2018

Conditions
Immune System Disorder
Interventions
DRUG

HLX03

A single dose of 40 mg HLX03 in 0.8 mL in subcutaneous injection.

DRUG

adalimumab

A single dose of 40 mg Humira in 0.8 mL in a pre-filled syringe

Trial Locations (1)

Unknown

the 1st affiliated hospital of Jilin University, Changchun

All Listed Sponsors
lead

Shanghai Henlius Biotech

INDUSTRY

NCT03357939 - Phase I Study of HLX3 vs Adalimumab in Chinese Healthy Subjects | Biotech Hunter | Biotech Hunter